NEW YORK, NY / ACCESSWIRE / May 29, 2023 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
TAL Education Group (NYSE:TAL)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tal-education-class-action-submission-form?prid=39986&wire=1
Lead Plaintiff Deadline: May 30, 2023
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired TAL American Depository Shares between June 14, 2022 and March 14, 2023, both dates inclusive.
Allegations against TAL include that: (1) the Company was still providing services relating to academic subjects to students from kindergarten through grade nine; and (2) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
Horizon Bancorp, Inc. (NASDAQ:HBNC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/horizon-class-action-submission-form?prid=39986&wire=1
Lead Plaintiff Deadline: June 20, 2023
Class Period: March 9, 2022 - March 10, 2023
Allegations against HBNC include that: (i) the Company maintained deficient internal accounting controls relating to its classification of certain loan balances and securities; (ii) as a result of the foregoing deficiencies, throughout 2022 the Company issued quarterly financial statements containing errors that would require subsequent revision; (iii) restatement of the foregoing financial statements would hinder the Company's ability to timely file its annual report for 2022; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fulcrum-class-action-submission-form?prid=39986&wire=1
Lead Plaintiff Deadline: June 27, 2023
Class Period: March 3, 2022 - March 8, 2023
Allegations against FULC include that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong